Loading...
OTCM
GNMLF
Market cap763mUSD
, Last price  
Name

Genomma Lab Internacional SAB de CV

Chart & performance

D1W1MN
OTCM:GNMLF chart
P/E
—
P/S
—
EPS
1.64
Vol. 1Y
—
Shs. 5Y
-0.76%
Rev. 5Y
4.81%
Div Yld LY
—
Div Yld TTM
—
Revenues
17.54b
-5.73%
1,373,480,0001,872,863,0002,629,430,0004,424,655,0006,263,621,0008,074,787,0009,799,690,00011,360,689,00011,540,998,00011,042,452,00011,316,310,00012,078,443,00011,794,419,00012,712,890,00013,870,148,00015,487,059,00016,819,912,00016,467,126,00018,606,903,00017,541,158,000
Net income
1.61b
+7.65%
180,301,000304,399,000515,776,000760,036,0001,092,958,0001,415,954,0001,504,004,0001,760,607,0001,444,558,000-1,068,519,000-1,680,925,0001,279,208,0001,109,465,000764,463,0001,403,503,0001,307,867,0001,389,203,0001,084,915,0001,493,122,0001,607,387,000
CFO
2.05b
-32.28%
-101,407,000103,331,000228,892,000385,519,000849,667,00089,212,000-107,086,0001,870,747,0001,038,596,000322,300,0001,674,845,0001,420,074,0001,562,479,0001,006,931,0001,714,525,0001,468,351,0002,054,793,0002,247,012,0003,033,717,0002,054,539,000
Dividend
Sep 29, 20260.0111 /sh
Earnings
Oct 21, 2026

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genomma Lab Internacional, S.A.B. de C.V., alongside its various operating units, specializes in the creation, promotion, and distribution of a wide array of over-the-counter (OTC) pharmaceutical goods and personal care items. Its operations span across Mexico and numerous international markets. The company's extensive product portfolio addresses diverse consumer needs, encompassing categories such as skincare, hair care, general health and wellness solutions, and pain management. Specific offerings include remedies for coughs and colds, digestive health aids, sexual well-being products, antiperspirants and deodorants, hand sanitizers, isotonic beverages, and shaving essentials. Beyond these, it also markets specialized pharmaceuticals such as analgesics, antifungals, and treatments for hemorrhoids. These products are brought to market under a multitude of well-known brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Established in 1996, Genomma Lab Internacional, S.A.B. de C.V. maintains its corporate headquarters in Mexico City, Mexico.

Key people

Juan Marco Sparvieri
Chief Executive Officer · since 2023
Jorge Luis Brake Valderrama
Vice Chairman of the Board · since 2023
Executive Chairman of the Board of Directors, Founding Partner · since 2019
Antonio Zamora Galland
Executive Vice President, Chief Financial and Administrative Officer · since 2015
Sabrina Lucila Herrera Aspra
Executive Director · since 2024
Alejandro Baston Patino
Executive Vice President - Institutional Affairs, Media, Human Resources and Sustainability · since 2020
Efrain Tapia Cordova
Non-Member Secretary of the Board of Directors · since 2025
Joaquin Ley Pinto
Director · since 2024
Simona Visztova
Director · since 2024
Juan Alonso
Independent Director · since 2008
Marco Francisco Forastieri Munoz
Independent Director · since 2020
Juan Carlos Gavito Aspe
Independent Director · since 2017
Ignacio Gonzalez Rodriguez
Independent Director · since 2017
Independent Director · since 2014
Javier Vale Castilla
Independent Director · since 2016
Independent Director · since 2018
IPO date
Jun 19, 2008
Employees
2,388
Domiciled in
MX
Incorporated in
MX

Valuation

Title
MXN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT